AMENDMENTS TO THE CLAIMS

1. (Original) A pyrazole derivative represented by general formula (1A) or (1B), or pharmaceutically acceptable salt thereof:



(1A)



(1B)

wherein X represents β-D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated; Y represents a lower alkyl group or a perfluoro lower alkyl group; Z represents a cyclic alkyl group which may have a substituent(s), a cyclic unsaturated alkyl group which may have a substituent(s), a lower alkyl group having a cyclic alkyl group which may have a substituent(s), or a lower alkyl group having a cyclic unsaturated alkyl group which may have a substituent(s); R1 to R5 may be the same or different and each represent a hydrogen atom, a lower alkyl group, a perfluoro lower alkyl group, a lower alkoxyl group, a perfluoro lower alkoxyl group, a lower alkylthio group, a perfluoro lower alkylthio group, a lower alkylamino group, a halogeno group, a lower alkanoyl group, an alkenyl group, a cyclic alkenyl group, an alkynyl group, a phenyl group which may have a substituent(s), or a lower alkoxycarbonyl group; and n is an integer of 0 to 3.

2. (Original) The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein, in formula (1A) or (1B), Y is trifluoromethyl group.

3. (Original) The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein, in formula (1A) or (1B), Y is trifluoromethyl group and n is 1.

4. (Original) The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein, in formula (1A) or (1B), Y is trifluoromethyl group, n is 1, and X is β-D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group.

5. (Original) The compound or pharmaceutically acceptable salt thereof according to claim 1, selected from the group consisting of compounds shown below:



(2)



(3)



(4)



(5)

6. (Previously Presented) A pharmaceutical composition comprising the pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1.

7. (Previously Presented) A therapeutic agent for diabetes comprising the pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1.

8. (Previously Presented) An agent for inducing urinary sugar excretion comprising the pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1.

9. (Previously Presented) A method for reducing renal glucose reabsorption at renal uriniferous tubules comprising administering the pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof.

10. (Currently Amended) A pyrazole-O-glycoside derivative represented by formula (I) or pharmaceutically acceptable salt thereof:



(I)



(I)

wherein X' represents β-D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated; Y' represents a hydrogen atom, a lower alkyl group, a fluoro lower alkyl group or a perfluoro lower alkyl group; Z' represents a halo lower alkyl group; and R_1' to R_5' may be the same or different and each represent a hydrogen atom, a halogeno group, a lower alkyl group, a halo lower alkyl group, a perfluoro lower alkyl group, a lower alkoxyl group, a perfluoro lower alkoxyl group, a lower alkylthio group, a perfluoro lower alkylthio group, a lower alkylamino group, a lower alkanoyl group, a lower alkenyl group, or a lower alkynyl group.

11. (Original) The pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10, wherein, in formula (I), X' is β-D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is trifluoromethyl group, and Z' is a halo lower alkyl group.

12. (Original) The pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10, wherein, in formula (I), X' is β-D-glucopyranosyl group wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is trifluoromethyl group, and Z' is a fluoro lower alkyl group.

13. (Original) The pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10, wherein, in formula (I), X' is β-D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is methyl group, and Z' is a halo lower alkyl group.

14. (Original) The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 10, wherein, in formula (I), X' is β-D-glucopyranosyl group, wherein one or more hydroxyl groups may be acylated with a group selected from the group consisting of an alkanoyl group having 2 to 20 carbon atoms, a lower alkoxycarbonyl group and a benzoyl group, Y' is methyl group, and Z' is a fluoro lower alkyl group.

15. (Original) The compound or pharmaceutically acceptable salt thereof according to claim 10, selected from the group consisting of compounds shown below:



(2)



(3)

16. (Previously Presented) A pharmaceutical composition comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10.

17. (Previously Presented) A therapeutic agent for diabetes comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10.

18. (Previously Presented) A therapeutic agent for diabetes for oral administration, comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10.

19. (Previously Presented) An agent for inducing urinary sugar excretion comprising the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10.

20. (Previously Presented) A method for reducing renal glucose reabsorption at renal uriniferous tubules comprising administering the pyrazole-O-glycoside derivative or pharmaceutically acceptable salt thereof according to claim 10 to a subject in need thereof.